ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

Childhood Cancer Survivors Do Not Have an Increased Risk Of Passing On Birth Defects

December 30, 2011

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

March 25, 2011

Michael Atkins Named Deputy Director at Georgetown Lombardi Cancer Center

March 2, 2012

President’s Cancer Panel Special Commission On Breast Cancer Named

April 25, 1992

Funding Opportunities

September 13, 2002

In Brief: Pitot Appointed To Cancer Panel, Replacing Jako; Fisher, Wattenberg, Curtiss Lead Cancer Groups

May 29, 1992